Literature DB >> 17307151

In vitro transfection of the hepatitis B virus PreS2 gene into the human hepatocarcinoma cell line HepG2 induces upregulation of human telomerase reverse transcriptase.

Hua Liu1, Fang Luan, Ying Ju, Hongyu Shen, Lifen Gao, Xiaoyan Wang, Suxia Liu, Lining Zhang, Wensheng Sun, Chunhong Ma.   

Abstract

The preS2 domain is the minimal functional unit of transcription activators that is encoded by the Hepatitis B virus (HBV) surface (S) gene. It is present in more than one-third of the HBV-integrates in HBV induced hepatocarcinoma (HCC). To further understand the functional role of PreS2 in hepatocytes, a PreS2 expression plasmid, pcS2, was constructed and stably transfected into HepG2 cells. We conducted growth curve and colony-forming assays to study the impact of PreS2 expression on cell proliferation. Cells transfected with PreS2 proliferated more rapidly and formed colonies in soft agar. PreS2 expressing cells also induced upregulation of human telomerase reverse transcriptase (hTERT) and telomerase activation by RT-PCR and the modified TRAP assay. Blocking expression of hTERT with antisense oligonuleotide reversed the growth rate in cells stably transfected with PreS2. Our data suggest that PreS2 may increase the malignant transformation of human HCC cell line HepG2 by upregulating hTERT and inducing telomerase activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307151     DOI: 10.1016/j.bbrc.2007.01.160

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  The role of cirrhosis in the etiology of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastrointest Cancer       Date:  2014-03

Review 2.  Infection, mutation, and cancer evolution.

Authors:  Paul W Ewald; Holly A Swain Ewald
Journal:  J Mol Med (Berl)       Date:  2012-04-04       Impact factor: 4.599

Review 3.  Viral hepatocarcinogenesis.

Authors:  W-L Tsai; R T Chung
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

4.  Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes.

Authors:  Liliana Terrin; Jessica Dal Col; Enrica Rampazzo; Paola Zancai; Moreno Pedrotti; Grazia Ammirabile; Stefano Bergamin; Silvana Rizzo; Riccardo Dolcetti; Anita De Rossi
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

5.  Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase.

Authors:  Hua Liu; Wei Shi; Fang Luan; Shifeng Xu; Fenghui Yang; Wensheng Sun; Jun Liu; Chunhong Ma
Journal:  Virus Genes       Date:  2010-01-28       Impact factor: 2.332

6.  Molecular mechanisms underlying hepatocellular carcinoma.

Authors:  Philippe Merle; Christian Trepo
Journal:  Viruses       Date:  2009-11-09       Impact factor: 5.048

7.  Herpesvirus telomerase RNA (vTR) with a mutated template sequence abrogates herpesvirus-induced lymphomagenesis.

Authors:  Benedikt B Kaufer; Sina Arndt; Sascha Trapp; Nikolaus Osterrieder; Keith W Jarosinski
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

8.  Cause-specific telomere factors deregulation in hepatocellular carcinoma.

Authors:  Manale El Idrissi; Valérie Hervieu; Philippe Merle; Franck Mortreux; Eric Wattel
Journal:  J Exp Clin Cancer Res       Date:  2013-09-11

9.  HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma.

Authors:  Peng Liu; Hualin Zhang; Xiaohong Liang; Hongxin Ma; Fang Luan; Bo Wang; Fuxiang Bai; Lifen Gao; Chunhong Ma
Journal:  Oncotarget       Date:  2015-10-06

10.  Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.

Authors:  Xiuming Liang; Jiping Zeng; Lixiang Wang; Ming Fang; Qing Wang; Min Zhao; Xia Xu; Zhifang Liu; Wenjuan Li; Shili Liu; Han Yu; Jihui Jia; Chunyan Chen
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.